You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
If the results are validated, investigators believe the method could help diagnose patients without the need for a needle biopsy and with fewer false positives.
InfanDx is taking the lead on the project and will be joined by researchers from University Hospital Essen, Clinic for Pediatrics I, and Furtwangen University.
The Stockholm-based company said it will use the funds to develop its metabolism-based liquid biopsy platform.
The test, which is in development using perspiration as a sample, has shown promising performance in a preliminary study.
By examining metagenomic data of bacterial species in a patient's gut, the researchers aim to improve diagnosis and long-term nutritional intervention and treatment.
Researchers in Nigeria are developing a handheld diagnostic device for identifying high-risk colorectal cancer patients in low-resource environments.
The firm will use the financing to commercialize a test that utilizes metabolomic and DNA biomarkers to characterize obesity and guide weight loss.
A tick-borne disease working group recommends the federal government explore using new technologies and repurposing existing ones to improve diagnosis.
A new study suggests binding proteins that target glucose or asparagine can be used in combination with cytolysin A-based nanopores to electrically detect the metabolites.
The handheld device uses CMOS technology for multiplexed measurement of disease-linked metabolites and could prove useful for inexpensive POC testing.